[go: up one dir, main page]

SMT202300308T1 - Anticorpi bi specifici anti-muc16-cd3 e coniugati anti-muc16 farmaco - Google Patents

Anticorpi bi specifici anti-muc16-cd3 e coniugati anti-muc16 farmaco

Info

Publication number
SMT202300308T1
SMT202300308T1 SM20230308T SMT202300308T SMT202300308T1 SM T202300308 T1 SMT202300308 T1 SM T202300308T1 SM 20230308 T SM20230308 T SM 20230308T SM T202300308 T SMT202300308 T SM T202300308T SM T202300308 T1 SMT202300308 T1 SM T202300308T1
Authority
SM
San Marino
Prior art keywords
muc16
antibodies
drug conjugates
specific
specific anti
Prior art date
Application number
SM20230308T
Other languages
English (en)
Inventor
Jessica R Kirshner
Thomas Nittoli
Marcus Kelly
Eric Smith
Lauric Haber
Sandra Coetzee
Alison Crawford
Yashu Liu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT202300308T1 publication Critical patent/SMT202300308T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20230308T 2016-09-23 2017-09-22 Anticorpi bi specifici anti-muc16-cd3 e coniugati anti-muc16 farmaco SMT202300308T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662399249P 2016-09-23 2016-09-23
US201762558711P 2017-09-14 2017-09-14
PCT/US2017/053113 WO2018067331A1 (en) 2016-09-23 2017-09-22 Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates
EP17784089.9A EP3515487B1 (en) 2016-09-23 2017-09-22 Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates

Publications (1)

Publication Number Publication Date
SMT202300308T1 true SMT202300308T1 (it) 2023-11-13

Family

ID=60083442

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20230308T SMT202300308T1 (it) 2016-09-23 2017-09-22 Anticorpi bi specifici anti-muc16-cd3 e coniugati anti-muc16 farmaco
SM20220359T SMT202200359T1 (it) 2016-09-23 2017-09-22 Anticorpi anti-muc16 (mucina 16)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM20220359T SMT202200359T1 (it) 2016-09-23 2017-09-22 Anticorpi anti-muc16 (mucina 16)

Country Status (29)

Country Link
US (4) US10738130B2 (it)
EP (3) EP3515946B1 (it)
JP (2) JP7066690B2 (it)
KR (2) KR102531251B1 (it)
CN (2) CN110214026B (it)
AU (2) AU2017331363B2 (it)
BR (2) BR112019005697A2 (it)
CA (2) CA3037738A1 (it)
CL (4) CL2019000712A1 (it)
CO (1) CO2019003967A2 (it)
DK (2) DK3515487T5 (it)
ES (2) ES2925563T3 (it)
FI (1) FI3515487T3 (it)
HR (2) HRP20221202T1 (it)
HU (2) HUE063020T2 (it)
IL (2) IL265309B2 (it)
LT (2) LT3515946T (it)
MD (1) MD3515487T2 (it)
MX (2) MX2019003326A (it)
MY (2) MY194596A (it)
NZ (2) NZ751903A (it)
PH (2) PH12019500550A1 (it)
PL (2) PL3515946T3 (it)
PT (2) PT3515946T (it)
RS (2) RS63660B1 (it)
SI (2) SI3515946T1 (it)
SM (2) SMT202300308T1 (it)
WO (2) WO2018067331A1 (it)
ZA (2) ZA201901557B (it)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
SMT202200050T1 (it) * 2015-09-23 2022-03-21 Regeneron Pharma Anticorpi bispecifici anti-cd3 ottimizzati e loro usi
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
CA3011942A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
SMT202300308T1 (it) * 2016-09-23 2023-11-13 Regeneron Pharma Anticorpi bi specifici anti-muc16-cd3 e coniugati anti-muc16 farmaco
IL313695A (en) * 2017-02-10 2024-08-01 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
RU2747095C2 (ru) * 2018-05-11 2021-04-26 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125
CN108659131B (zh) * 2018-05-28 2021-09-14 长春力太生物技术有限公司 一种抗ceacam-5的单域抗体及其应用
TW202504917A (zh) * 2018-06-21 2025-02-01 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法
MX419677B (es) 2018-06-21 2025-01-14 Regeneron Pharma Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CN119954969A (zh) 2018-07-19 2025-05-09 瑞泽恩制药公司 具有bcma特异性的嵌合抗原受体及其用途
KR20210049863A (ko) 2018-08-23 2021-05-06 리제너론 파아마슈티컬스, 인크. 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도
PL3844189T3 (pl) 2018-08-31 2025-03-31 Regeneron Pharmaceuticals, Inc. Strategia dawkowania, która łagodzi zespół uwalniania cytokin, dla przeciwciał dwuswoistych cd3/cd20
CA3116717A1 (en) 2018-10-31 2020-05-07 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
MX2021005751A (es) * 2018-11-16 2021-10-01 Memorial Sloan Kettering Cancer Center Anticuerpos contra mucina 16 y métodos de uso de los mismos.
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
KR20210104836A (ko) 2018-12-19 2021-08-25 리제너론 파아마슈티컬스, 인크. 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도
MA54539A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
PH12021552300A1 (en) 2019-03-22 2022-07-04 Regeneron Pharma EGFR x CD28 MULTISPECIFIC ANTIBODIES
KR20220007873A (ko) * 2019-05-08 2022-01-19 메모리얼 슬로안 케터링 캔서 센터 뮤신-16에 대한 인간화된 항체 및 이의 사용 방법
WO2020256721A1 (en) * 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
AU2020294790A1 (en) * 2019-06-21 2021-12-16 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
CA3143478A1 (en) * 2019-07-09 2021-01-14 Tomer Hertz Antibodies with reduced immunogenicity
TWI890689B (zh) * 2019-08-15 2025-07-21 美商再生元醫藥公司 用於細胞靶向之多特異性抗原結合分子及其用途
WO2021032174A1 (zh) * 2019-08-21 2021-02-25 和铂医药(上海)有限责任公司 一种抗cd47抗原结合蛋白及其应用
EP4025605A1 (en) * 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73 antibodies
US11814428B2 (en) * 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
AU2020398167A1 (en) * 2019-12-06 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
MY190623A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
AR124448A1 (es) * 2020-12-22 2023-03-29 Amgen Inc Ensayo de gradiente de difusión para moléculas que contienen anti-cd3
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
TW202304507A (zh) * 2021-04-02 2023-02-01 美商再生元醫藥公司 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物
WO2022263507A1 (en) 2021-06-17 2022-12-22 Boehringer Ingelheim International Gmbh Novel tri-specific binding molecules
JP2024542536A (ja) 2021-11-24 2024-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｃｄ３×ｍｕｃ１６抗体及び抗ｃｔｌａ－４抗体を用いてがんを治療するための方法
EP4460520A1 (en) 2022-01-07 2024-11-13 Regeneron Pharmaceuticals, Inc. Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
WO2023131328A1 (zh) * 2022-01-10 2023-07-13 南京维立志博生物科技有限公司 一种抗体及其用途
EP4463471A2 (en) * 2022-01-10 2024-11-20 Regeneron Pharmaceuticals, Inc. Muc16 chimeric antigen receptors
KR20240159849A (ko) 2022-03-17 2024-11-06 리제너론 파아마슈티컬스, 인크. 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와 병용으로 재발성 상피 육종을 치료하는 방법
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Compositions and methods for universal tumor cell killing
WO2024051752A1 (en) * 2022-09-06 2024-03-14 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
WO2024123698A1 (en) 2022-12-08 2024-06-13 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
KR20250151441A (ko) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포
CN120916782A (zh) 2023-03-13 2025-11-07 里珍纳龙药品有限公司 用双特异性抗cd22×抗cd28分子治疗癌症的方法
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina
AU2024297594A1 (en) 2023-07-10 2026-01-29 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1xcd28 antibodies and methods of use thereof
AU2024287529A1 (en) 2023-07-10 2026-02-05 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1x4-1bb antibodies and methods of use thereof
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像
WO2025080540A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine
CN119978126A (zh) * 2023-11-10 2025-05-13 深圳市菲鹏生物治疗股份有限公司 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用
WO2025104253A1 (en) * 2023-11-17 2025-05-22 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
TW202539732A (zh) 2023-11-29 2025-10-16 美商再生元醫藥公司 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
TW202542187A (zh) 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法
WO2026015612A1 (en) 2024-07-10 2026-01-15 Regeneron Pharmaceuticals, Inc. Methods of treating smarcb1-deficient cancers

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
AU2002254615A1 (en) 2001-04-17 2002-10-28 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
ATE293794T1 (de) 2001-12-04 2005-05-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von ca 125
ATE502051T1 (de) 2002-10-16 2011-04-15 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2144628B1 (en) * 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CA2687178C (en) 2007-05-23 2014-02-04 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
US8187801B2 (en) * 2008-04-24 2012-05-29 Wisconsin Alumni Research Foundation Methods and kits to detect and monitor ovarian cancer and preeclampsia
AU2009243009B2 (en) 2008-04-30 2014-09-11 Immunogen, Inc Potent conjugates and hydrophilic linkers
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
AU2011230590C1 (en) * 2010-03-26 2016-09-15 Memorial Sloan-Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
TWI540136B (zh) 2010-04-15 2016-07-01 梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
WO2012070029A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103987384A (zh) 2011-10-14 2014-08-13 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
KR101961976B1 (ko) 2011-10-14 2019-03-25 시애틀 지네틱스, 인크. 피롤로벤조디아제핀 및 표적 접합체
WO2013053872A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
CA2850103C (en) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
EP2968593B1 (en) 2013-03-15 2024-11-20 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
HRP20240939T1 (hr) * 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US11066480B2 (en) 2015-03-17 2021-07-20 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
CA2978340C (en) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
SMT202200050T1 (it) * 2015-09-23 2022-03-21 Regeneron Pharma Anticorpi bispecifici anti-cd3 ottimizzati e loro usi
SMT202300308T1 (it) 2016-09-23 2023-11-13 Regeneron Pharma Anticorpi bi specifici anti-muc16-cd3 e coniugati anti-muc16 farmaco

Also Published As

Publication number Publication date
ES2925563T3 (es) 2022-10-18
US11485793B2 (en) 2022-11-01
ZA201901557B (en) 2024-08-28
BR112019005697A2 (pt) 2019-07-16
WO2018067331A1 (en) 2018-04-12
IL265369A (en) 2019-05-30
WO2018058003A1 (en) 2018-03-29
MX2019003322A (es) 2019-08-05
MY200230A (en) 2023-12-15
US20200317810A1 (en) 2020-10-08
JP2019536740A (ja) 2019-12-19
CO2019003967A2 (es) 2019-05-10
NZ751903A (en) 2025-09-26
WO2018067331A9 (en) 2018-06-07
KR102531251B1 (ko) 2023-05-15
ZA201901591B (en) 2024-05-30
CL2023002690A1 (es) 2024-02-02
MD3515487T2 (ro) 2023-11-30
RS64691B1 (sr) 2023-11-30
RS63660B1 (sr) 2022-11-30
US20180118848A1 (en) 2018-05-03
IL265309B2 (en) 2024-04-01
KR20190067808A (ko) 2019-06-17
CN110214026A (zh) 2019-09-06
HUE063020T2 (hu) 2023-12-28
US20230272111A1 (en) 2023-08-31
FI3515487T3 (fi) 2023-08-15
EP3515487B1 (en) 2023-07-19
IL265369B1 (en) 2023-11-01
ES2952735T3 (es) 2023-11-03
LT3515487T (lt) 2023-08-25
KR102418667B1 (ko) 2022-07-12
CN110036032B (zh) 2023-09-05
PH12019500604A1 (en) 2019-06-03
IL265369B2 (en) 2024-03-01
AU2017339711A1 (en) 2019-04-11
CL2019000726A1 (es) 2019-05-31
LT3515946T (lt) 2022-08-10
MX2019003326A (es) 2019-09-10
JP7066690B2 (ja) 2022-05-13
HRP20221202T1 (hr) 2022-12-09
CA3037536A1 (en) 2018-03-29
CN110214026B (zh) 2023-12-05
US10738130B2 (en) 2020-08-11
CN110036032A (zh) 2019-07-19
DK3515487T3 (da) 2023-08-28
JP2019533807A (ja) 2019-11-21
DK3515487T5 (da) 2024-09-02
HRP20231281T1 (hr) 2024-02-02
BR112019005670A2 (pt) 2019-06-04
PT3515487T (pt) 2023-08-24
AU2017331363A1 (en) 2019-04-11
CL2019000712A1 (es) 2019-05-31
IL265309B1 (en) 2023-12-01
US10941208B2 (en) 2021-03-09
IL265309A (en) 2019-05-30
US20180112001A1 (en) 2018-04-26
SMT202200359T1 (it) 2022-11-18
AU2017331363B2 (en) 2024-06-13
AU2017339711B2 (en) 2024-06-06
DK3515946T5 (da) 2024-09-02
EP3515487A1 (en) 2019-07-31
JP7066691B2 (ja) 2022-05-13
NZ751907A (en) 2025-09-26
CA3037738A1 (en) 2018-04-12
PH12019500550A1 (en) 2019-05-27
CL2021002645A1 (es) 2022-04-29
EP3515946A1 (en) 2019-07-31
EP3515946B1 (en) 2022-07-06
SI3515487T1 (sl) 2023-09-29
MY194596A (en) 2022-12-06
KR20190073377A (ko) 2019-06-26
EP4273172A2 (en) 2023-11-08
PT3515946T (pt) 2022-08-04
PL3515946T3 (pl) 2022-11-07
PL3515487T3 (pl) 2024-01-15
SI3515946T1 (sl) 2022-09-30
EP4273172A3 (en) 2024-02-28
DK3515946T3 (en) 2022-08-01
HUE059761T2 (hu) 2022-12-28

Similar Documents

Publication Publication Date Title
IL265309A (en) Bispecific antibodies against MUC16 and CD3 and drug conjugates against MUC16
IL290457A (en) Antibodies and their conjugates
ZA202007918B (en) Anti-cd123 antibodies and conjugates and derivatives thereof
IL291073A (en) Drug conjugates of anti-egfr antibodies
ZA201900059B (en) Anti-b7-h3 antibodies and antibody drug conjugates
IL251938A0 (en) Antibodies against CS1 and antibody-drug conjugates
IL267834B1 (en) Conjugates of drug and antibody against ccr7
IL255526A (en) Cd123 antibodies and their couplings
IL247936A0 (en) Antibodies against egfr and drug antibody conjugates
IL252015A0 (en) Antibody drug conjugates
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
IL254027B (en) cd48 antibodies and their conjugates
IL265362A (en) Anti-c-met antibodies and drug conjugates containing such antibodies
SG10202006863YA (en) Cl and/or ch1 mutated antibodies for drug conjugation
PL3544634T3 (pl) Koniugaty przeciwciało MET-lek
LU92659B1 (en) Glycooptimized antibody drug conjugates